2022 annual financial data
BioCryst Pharmaceuticals 2022 Operating cash flow margin
Direct answer
Operating cash flow margin was -59.76%.
Operating income was -148,435,000 USD and net income was -247,116,000 USD.
Operating cash flow was -161,850,000 USD.
Get free BioCryst Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 270,827,000 USD
- Operating income
- -148,435,000 USD
- Net income
- -247,116,000 USD
- Operating cash flow
- -161,850,000 USD